A membrane-associated MHC-I inhibitory axis for cancer immune evasion

[1]  J. Byrd,et al.  An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia , 2022, Nature Cancer.

[2]  Xiao-Dan Zhu,et al.  Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression , 2022, Nature Communications.

[3]  G. De Libero,et al.  Mitochondrial Proteins as Source of Cancer Neoantigens , 2022, International journal of molecular sciences.

[4]  M. Bhasin,et al.  Survival Genie, a web platform for survival analysis across pediatric and adult cancers , 2021, Scientific Reports.

[5]  T. Rodríguez,et al.  MHC-I presents: tumor surveillance in the epithelia by cell competition , 2021, Nature Immunology.

[6]  D. Dima,et al.  Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia? , 2021, Pharmaceuticals.

[7]  K. Rock,et al.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation , 2021, Frontiers in Immunology.

[8]  C. Hammer,et al.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion , 2021, Nature Reviews Cancer.

[9]  R. Tampé,et al.  MHC I assembly and peptide editing - chaperones, clients, and molecular plasticity in immunity. , 2021, Current opinion in immunology.

[10]  Clifford A. Meyer,et al.  Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. , 2021, Cancer discovery.

[11]  M. Raaben,et al.  The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses. , 2021, Immunity.

[12]  John G Doench,et al.  In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. , 2021, Immunity.

[13]  Chunsheng Zhang,et al.  STUB1 is an intracellular checkpoint for interferon gamma sensing , 2020, Scientific Reports.

[14]  Jesse H. Arbuckle,et al.  Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. , 2020, Immunity.

[15]  Chuan-Yuan Li,et al.  PCSK9 inhibition potentiates cancer immune checkpoint therapy , 2020, Nature.

[16]  J. Yewdell,et al.  A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion , 2020, Nature Reviews Immunology.

[17]  R. Aguiar,et al.  Functional characterization of TMEM127 variants reveals novel insights into its membrane topology and trafficking. , 2020, The Journal of clinical endocrinology and metabolism.

[18]  J. Pruneda,et al.  The Tumour Suppressor TMEM127 Is a Nedd4-Family E3 Ligase Adaptor Required by Salmonella SteD to Ubiquitinate and Degrade MHC Class II Molecules , 2020, Cell host & microbe.

[19]  J. Debnath,et al.  Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I , 2020, Nature.

[20]  Shixiang Wang,et al.  Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction , 2019, eLife.

[21]  E. Mardis.  Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response , 2019, Genome Medicine.

[22]  R. Tothill,et al.  An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer , 2019, Cancer cell.

[23]  A. Brass,et al.  Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression , 2019, The Journal of Immunology.

[24]  T. Sakellaropoulos,et al.  Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. , 2019, Cancer discovery.

[25]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[26]  P. van Endert,et al.  Endocytic Recycling of MHC Class I Molecules in Non-professional Antigen Presenting and Dendritic Cells , 2019, Front. Immunol..

[27]  T. Schumacher,et al.  Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers , 2018, Nature Medicine.

[28]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[29]  P. Cresswell,et al.  A novel probe to assess cytosolic entry of exogenous proteins , 2018, Nature Communications.

[30]  P. Cresswell,et al.  Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I , 2018, The Journal of Biological Chemistry.

[31]  Guoping Cai,et al.  Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. , 2017, Cancer discovery.

[32]  I. Melero,et al.  Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[34]  C. Foglieni,et al.  Split GFP technologies to structurally characterize and quantify functional biomolecular interactions of FTD-related proteins , 2017, Scientific Reports.

[35]  R. Palmqvist,et al.  TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer , 2017, Oncoimmunology.

[36]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[37]  N. Sato,et al.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition , 2017, Oncoimmunology.

[38]  R. Yuan,et al.  PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective , 2017, Journal of Hematology & Oncology.

[39]  S. Burrows,et al.  CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold , 2016, Immunology and cell biology.

[40]  V. Driss,et al.  A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model , 2016, Journal of visualized experiments : JoVE.

[41]  I. Cebrian,et al.  Rab22a controls MHC‐I intracellular trafficking and antigen cross‐presentation by dendritic cells , 2016, EMBO reports.

[42]  Christine E Brown,et al.  Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer , 2016, Clinical Cancer Research.

[43]  M. Shipp,et al.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer , 2016, Proceedings of the National Academy of Sciences.

[44]  Brock F. Binkowski,et al.  NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. , 2016, ACS chemical biology.

[45]  H. Einsele,et al.  Karyotype complexity and prognosis in acute myeloid leukemia , 2016, Blood Cancer Journal.

[46]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[47]  Ole Winther,et al.  BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis , 2015, Nucleic Acids Res..

[48]  A. Bax,et al.  A Novel MHC-I Surface Targeted for Binding by the MCMV m06 Immunoevasin Revealed by Solution NMR* , 2015, The Journal of Biological Chemistry.

[49]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[50]  T. Rau,et al.  Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer , 2015, Journal of Translational Medicine.

[51]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[52]  S. Srikantan,et al.  The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. , 2014, Human molecular genetics.

[53]  Christof Fellmann,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[54]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[55]  Hau B. Nguyen,et al.  A New Protein-Protein Interaction Sensor Based on Tripartite Split-GFP Association , 2013, Scientific Reports.

[56]  P. Lehner,et al.  MHC class I molecules are preferentially ubiquitinated on endoplasmic reticulum luminal residues during HRD1 ubiquitin E3 ligase-mediated dislocation , 2013, Proceedings of the National Academy of Sciences.

[57]  Chunlei Wu,et al.  BioGPS and MyGene.info: organizing online, gene-centric information , 2012, Nucleic Acids Res..

[58]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[59]  Jing Liu,et al.  Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin , 2011, Proceedings of the National Academy of Sciences.

[60]  Sébastien Lemieux,et al.  The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation , 2011, Molecular systems biology.

[61]  Chi-Jung Huang,et al.  A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment , 2011, Journal of Translational Medicine.

[62]  Christof Fellmann,et al.  Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.

[63]  Patricia L. M. Dahia,et al.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma , 2010, Nature Genetics.

[64]  M. Ressing,et al.  The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation , 2009, PLoS pathogens.

[65]  P. Cresswell,et al.  Regulation of MHC class I assembly and peptide binding. , 2008, Annual review of cell and developmental biology.

[66]  R. Weigert,et al.  Rab22a regulates the recycling of membrane proteins internalized independently of clathrin. , 2004, Molecular biology of the cell.

[67]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[68]  K. Schroder,et al.  Interferon‐γ: an overview of signals, mechanisms and functions , 2004 .

[69]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[70]  G. Balendiran,et al.  Definition and transfer of a serological epitope specific for peptide-empty forms of MHC class I. , 1999, International immunology.

[71]  J. Bryant,et al.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.

[72]  C. Meijer,et al.  Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas , 1994, The Journal of experimental medicine.

[73]  N. Shastri,et al.  Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Hidde L. Ploegh,et al.  Empty MHC class I molecules come out in the cold , 1990, Nature.

[75]  A. Ribas,et al.  Mechanisms of Resistance to PD-1 and PD-L1 Blockade , 2018, Cancer journal.